mRNA tumor vaccines

Phase 1Vaccine

FFudan University

mRNA tumor vaccines is one of 5 small molecule programs targeting Pancreatic. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PancreaticNot yet recruiting

PancreaticPhase 1

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Pancreatic

#DrugCompanyPhaseTrials

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1

1 2

Pancreatic Parenchymal of N-Butyl-2-Cyanoacrylate

MMinia University

Phase 2

1 3

mRNA tumor vaccines

FFudan University

Phase 1

1 4

Synthetic Human Secretin

MMayo Clinic

Preclinical

2 5

Proton Pump Inhibitors

SSamsung Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Pancreatic

NCT06156267

Clinical

Trials by Indication[1]

Pancreatic1 trial

Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino

Not yet recruiting·FFudan University·Phase 1·NCT06156267·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for mRNA tumor vaccines. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mRNA tumor vaccines compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mRNA tumor vaccines. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 1[1]
Company: FFudan University

mRNA tumor vaccines

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Pancreatic1 trial

References

Drug Info

Quick Facts

Related News